Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Nov 15, 2018; 10(11): 421-430
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.421
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.421
Figure 1 Flow chart of patient selection.
G-CSF: granulocyte colony stimulating factor.
Figure 2 Survival analyses and comparisons.
A: Progression-free survival; B: Overall survival, according to the treatment group. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX.
- Citation: Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430
- URL: https://www.wjgnet.com/1948-5204/full/v10/i11/421.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.421